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Abstract
The impact of bloodstream infection (BSI) on admission to hospital on the outcome of patients with community-acquired sepsis (CAS)
admitted to intensive-care units (ICU) is largely unknown. We selected 803 adult patients consecutively admitted with CAS to one of
17 Portuguese ICU, in whom blood cultures were collected before initiation of antibiotic therapy during a 12-month period. A BSI was
identiﬁed on hospital admission in 160 (19.9%) patients. Those with and without BSI had similar mean Simpliﬁed Acute Physiology Score
(SAPS) II and age. The presence of BSI was independently associated with mortality in ICU (adjusted odds ratio 1.86; 95% conﬁdence
interval 1.20–2.89; p 0.005). On the 4th day in ICU, patients with BSI were found to be signiﬁcantly more dependent on vasopressor
support (p 0.002) but not on ventilatory support. Cumulative ICU mortality was signiﬁcantly higher in BSI patients from the 9th day
onwards. A seasonal variation of BSI isolates was noted: gram-negative BSI were more common in the summer, whereas in the winter,
gram-positive infections were more frequent (p 0.024), without mortality differences.
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Introduction
Despite great advances in the understanding of its patho-
physiology, severe sepsis remains associated with high
mortality, morbidity and costs [1]. Microbiological documen-
tation, particularly of bloodstream infections (BSI), occurs in
only a fraction of patients with community-acquired sepsis
(CAS) [2].
The Surviving Sepsis Campaign guidelines [3] reinforce the
need for obtaining blood cultures before starting antibiotic
therapy in patients with CAS and with a high risk of dying to
identify the causative microorganism and target antibiotic
therapy. Our group, the SACiUCI (Sepsis Adquirida na Comun-
idade e internada em Unidade de Cuidados Intensivos) study
group, had already shown that performing blood cultures in
patients with severe sepsis and septic shock was indepen-
dently associated with improved survival [4].
Hospital-acquired BSI is associated with excess length of
stay, extra costs and excess mortality in critically ill patients
[5]. However, data on BSI in patients with CAS is scarce.
Furthermore, it is not known if the presence of a BSI by
itself, complicating an identiﬁable focus of CAS, e.g. pneumo-
nia or peritonitis, increases the risk of death.
In this study, we evaluate the impact of BSI on the mortal-
ity of patients with severe CAS.
Methods
The SACiUCI study is a prospective, multi-centre, observa-
tional study designed to evaluate the epidemiology of CAS in
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patients admitted to Portuguese intensive-care units (ICUs).
A detailed description of the study has been previously pub-
lished [4,6,7]. Brieﬂy, all patients older than18 years, newly
admitted to the 17 participating ICUs, were consecutively
enrolled during a 12-month period and followed up until
death or hospital discharge. The study design was approved
by the local Hospital Ethics Committees. Informed consent
was waived because of the study’s observational nature.
Patients with CAS, deﬁned as the onset of infection
before hospital admission or not present at admission but
that became evident in the ﬁrst 48 h, were eligible for fur-
ther analyses. Presence of sepsis, severe sepsis or septic
shock was deﬁned according to the American College of
Chest Physicians/Society of Critical Care Medicine Consen-
sus Conference criteria [8]. The presence of healthcare-asso-
ciated infection (HCAI) was deﬁned at hospital admission
according to the presence of the following criteria: home
infusion therapy or wound care; chronic dialysis or chemo-
therapy within 30 days; hospitalization for 2 days or more in
the preceding 90 days; residence in a nursing home or
extended-care facility [9]. Episodes of CAS were divided
according to the primary infection focus. All data were man-
aged by the Department of Biostatistics and Medical Infor-
matics at the University of Porto, where a dedicated
database for SACiUCI had been created.
All patients consecutively admitted with CAS who had
blood cultures collected before initiation of antibiotic ther-
apy constituted our study population. Data collection
included demographic data and co-morbid diseases, clinical
and laboratory data from hospital admission to the 5th ICU
day (including C-reactive protein and temperature). The Sim-
pliﬁed Acute Physiology Score (SAPS) II was computed for
all included patients [10]. The days of ICU and hospital dis-
charge were recorded. Microbiological and clinical infectious
data were reported, along with the antibiotics prescribed.
The microorganism’s sensitivity to the antibiotics prescribed
on the day of hospital admission was available in 343 of the
364 patients with positive microbiological cultures. Blood
culture collection on the day of hospital admission and its
results were closely scrutinized. Blood cultures with isolated
microorganisms considered most likely to be contaminants
were considered negative for further analyses. Patients’ ICU
and hospital outcomes, either discharge or death, were our
primary outcome measures. Comparison between survivors
and non-survivors was performed.
Statistical analysis
A single investigator in each participating centre performed
data entry. Consistency of data was assessed with a recheck-
ing procedure of a 10% random sample of patients (see
Acknowledgements). Data were screened in detail (see
Acknowledgements) for missing information and for implausi-
ble and outlying values.
Continuous variables were expressed as median (inter-
quartile range) or mean ± SD according to data distribution.
Comparisons between groups were performed with two-
tailed unpaired Student’s t test or Mann–Whitney U test for
continuous variables according to data distribution. Fisher’s
exact test and chi-squared test were used to test association
between categorical variables as appropriate.
A multiple logistic regression was ﬁtted to assess the
impact of BSI on mortality in patients with CAS, adjusting for
age, SAPS II, sepsis severity, the presence of HCAI, and pri-
mary infection focus. Adjusted odds ratios (AOR) with 95%
CI were computed.
The Hosmer and Lemeshow test was used to check good-
ness-of-ﬁt.
Cumulative mortality for each day in the ICU was calcu-
lated for CAS patients either with or without BSI.
Data were analysed using PASW STATISTICS v.18.0 FOR MAC
(SPSS, Chicago, IL, USA). All statistics were two-tailed, and
signiﬁcance level was deﬁned as p <0.05.
Results
General description and outcomes
A total of 897 patients with CAS were included. In 94
patients, blood cultures were not performed on the day of
hospital admission, resulting in 803 patients for analysis (age
58.4 ± 17.8 years; 65.3% male). At ICU admission their mean
score on SAPS II was high, 47.9 ± 17.9, and 51% of the
patients were in septic shock (Table 1). The overall ICU and
hospital mortalities were 29% and 37%, respectively.
In 160 patients with CAS (19.9%) blood cultures returned
positive. Patients with and without BSI had similar mean age
and SAPS II. Nevertheless, the rate of septic shock at
ICU admission was higher in patients with BSI (Table 1),
although not reaching statistical signiﬁcance (58.8% versus
50.5%, p 0.086).
The main primary focus of infection in our patient popula-
tion was the lung (60.6%); however, among the patients with
BSI, only 36.9% had a lower respiratory tract primary infec-
tion focus. In contrast, despite the fact that the urinary tract
was the primary infection focus in only 7.8% of CAS patients,
it was present in 16.3% of the BSI episodes (p <0.001)
(Table 1).
In the multivariable analysis, the presence of BSI at hospi-
tal admission was found to be independently associated with
ICU mortality, 39.4% versus 26.4%, (AOR 1.86; 95% CI
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1.20–2.89; p 0.005; Hosmer and Lemeshow test: p 0.482;
v2 = 7.52).
In the sub-groups of patients with the primary focus of
infection in the lung (n = 486) or intra-abdominally
(n = 135), the presence of BSI at hospital admission was also
associated with an increased risk of dying while in the ICU
(42.4% versus 27.2%; p 0.016 and 46.7% versus 25.7%; p
0.028, respectively).
Clinical course
In Table 2, we present the mortality rate at day 4 of ICU
stay and the persistence of organ support dependence in
CAS patients who were still alive (n = 754). We found that
the presence of BSI was associated with a higher rate of
vasopressor support dependence (40.9% versus 27.1%,
p 0.002) but not of ventilatory support. Mortality rate was
not different at that time-point. Finally, despite the fact that
ICU mortality and hospital mortality were higher in patients
with BSI at hospital admission, this difference only became
signiﬁcant from the 9th day of the ICU stay (Fig. 1).
BSI microbiology
The microorganisms isolated from blood cultures are listed
in Table 3. One single agent was found in 80.6% of BSI. One
hundred gram-positive bacteria were isolated in blood cul-
tures, mainly Streptococcus pneumoniae and methicillin-sensi-
tive Staphylococcus aureus. Roughly the same number of
gram-negative bacteria (93) were identiﬁed. Enterobacteria-
ceae, essentially Escherichia coli and also Klebsiella pneumoniae,
were the commonest.
The adequacy of empirical antibiotic prescription at hospi-
tal admission was 81.6%. Concerning only patients with a BSI
we found an adequacy rate of 85.4%. The ICU mortality of
those BSI patients who receive adequate empirical antibiotic
therapy was 41.5%, lower than, although not signiﬁcantly dif-
ferent from, those with inadequate antibiotics, 52.4% (p 0.49).
No signiﬁcant association was found between the type of
microorganism responsible for the BSI and mortality. The
ICU mortality of patients with gram-negative BSI was 33.3%,
with gram-positive BSI was 49.3%, and with mixed microor-
ganisms BSI was 38.9% (p 0.176).
TABLE 1. Baseline characteristics of community-acquired sepsis patients at intensive-care unit admission
Total (n = 804) No BSI (n = 644) BSI (n = 160) p-value
Age, years 58.4 ± 17.8 58.8 ± 18 56.8 ± 17.6 0.419§
Males 525 (65.3%) 426 (66.1%) 99 (61.9%) 0.309*
SAPS II 47.9 ± 17.9 47.7 ± 17.6 48.3 ± 18.7 0.814§
Primary admission diagnosis
Medical 637 (79.2%) 504 (78.3%) 133 (83.1%) 0.034*
Trauma 35 (4.4%) 34 (5.3%) 1 (0.6%)
Surgery 132 (16.4%) 106 (16.5%) 26 (16.3%)
Community-acquired sepsis primary infection focus
Lung 487 (60.6%) 428 (66.5%) 59 (36.9%) <0.001*
Urinary 63 (7.8%) 37 (5.7%) 26 (16.3%)
Intra-abdominal 135 (16.8%) 105 (16.3%) 30 (18.8%)
Other 119 (14.8%) 74 (11.5%) 45 (28.1%)
HCAI 189 (23.5%) 139 (21.6%) 50 (31.3%) 0.010*
Antibiotic adequacya 280 (81.6%) 157 (78.9%) 123 (85.4%) 0.3*
Temperature (C) 37.5 (1.5) 37.5 (1.4) 37.8 (1.7) 0.010§
C-reactive protein (mg/dL) 19.4 (18.5) 18.4 (18) 22.3 (18.2) 0.007**
WBC (·103/mm3) 12 (11) 12 (10) 13 (13) 0.286**
Sepsis severity
Sepsis 67 (8.3%) 59 (9.2%) 8 (5.0%) 0.086*
Severe sepsis 318 (39.6%) 260 (40.4%) 58 (36.3%)
Septic shock 419 (52.1%) 325 (50.5%) 94 (58.8%)
ICU LOS (days) 9 (10) 9 (10) 9 (13) 0.962**
Hospital LOS (days) 19 (19) 19 (18) 18 (12) 0.111**
ICU mortality 233 (29.0%) 170 (26.4%) 63 (39.4%) 0.001*
Hospital mortality 297 (37.2%) 225 (35.1%) 72 (45.6%) 0.015*
*Chi-square test, **Mann–Whitney U test, §Student’s t-test.
aOnly patients with positive microbiological cultures and susceptibility antibiotic testing results available were included.
Signiﬁcant p-values are indicated in bold.
Patients included with blood cultures performed on the day of hospital admission; data presented as mean ± SD, median (interquartile range) or n (%).
BSI, bloodstream infection; HCAI, healthcare-associated infection; ICU, intensive-care unit; LOS, length of stay; SAPS II, Simpliﬁed Acute Physiology Score II; WBC, white
blood cell count.
TABLE 2. Mortality of community-acquired sepsis patients
according to the presence or absence of bloodstream infec-
tion at day 4 in the intensive-care unit stay and the need for
ventilatory and vasopressor support of those still alive
Total
(n = 804)
No BSI
(n = 644)
BSI
(n = 160) p-value*
Mortality at day 4 87 (11) 66 (10) 21 (13) 0.298
Patients alive at day 4
With ventilatory support 544 (78) 436 (78) 108 (79) 0.887
With vasopressor support 210 (30) 154 (27) 56 (41) 0.002
*Chi-square test.
Data presented as n (%).
BSI, bloodstream infection.
Siginiﬁcant p-values are indicated in bold.
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Seasonal variation of BSI microbiology
Patients with a monomicrobial BSI who were admitted dur-
ing the winter were more likely to have a gram-positive
infection, whereas those admitted in the summer were more
prone to gram-negative agents (p 0.024) (Table 4). This
seems to be largely the result of the different primary infec-
tion foci, namely more lung infections in the winter and a
relative increase in the proportion of both intra-abdominal
and urinary tract infections during the rest of the year.
Discussion
In our study we found that the presence of BSI in patients
with CAS was independently associated with both ICU and
hospital mortality. However, this difference became signiﬁ-
cant relatively late in the clinical course, only after the 9th
day of ICU stay. We also report a seasonal variation in
microbiological isolates in CAS patients, with gram-positive
microorganisms more frequent during the winter and gram-
negative organisms more common in the summer.
In a population-based study, the incidence of BSI was
found to be 15.7/100 000 patients per year [11] and was
associated with risk factors for severe infection, namely age
over 65 years, male gender, cancer, alcoholism, diabetes,
lung disease and admission to an urban hospital. In another
cohort of 3901 patients with CAS, the incidence of BSI at
hospital admission was 8.2% [12]. In that study the major
clinical predictors of BSI were high temperature (>39.5C),
the presence of a central venous line and the suspicion of
endocarditis. The authors concluded that it was possible to
safely reduce the collection of blood cultures in 26.7% with-
out compromising safety. In fact, of a sub-group of 30 low-
risk patients discharged home (25 with an antibiotic prescrip-
tion) who were ultimately found to have a BSI, only seven
had deteriorated when they returned for a second hospital
evaluation [13]. In contrast, in our cohort of CAS patients
the performance of blood cultures was independently associ-
ated with lower mortality [4]. However, all our patients
needed ICU admission. Similarly in a study of 209 patients
with community-acquired pneumonia [14], blood cultures
only proved to be useful, providing guidance for antibiotic
FIG. 1. Cumulative mortality of patients with community-acquired sepsis according to the presence of positive blood cultures on the day of hos-
pital admission. A signiﬁcantly higher mortality was noted from the 9th day onwards in patients with bloodstream infection. Chi-square test;
*p <0.05.
TABLE 3. Main microorganisms isolated in bloodstream
infections
Species n
All gram-negative 93
Aeromonas hydrophila 1
Burkholderia cepacia 1
Citrobacter species 5
Eikenella corrodens 1
Enterobacter aerogenes 1
Enterobacter cloacae 1
Escherichia coli 44
Haemophilus inﬂuenzae 4
Klebsiella pneumoniae 15
Klebsiella species 2
Morganella morganii 1
Proteus mirabilis 4
Providencia species 1
Pseudomonas aeruginosa 7
Salmonella species 2
Serratia marcescens 1
Stenotrophomonas maltophilia 2
All gram-positive 100
Enterococcus faecalis 14
Enterococcus faecium 4
Staphylococcus aureusa 36
Coagulase-negative Staphylococcus 6
Streptococcus species 6
Streptococcus pneumoniae 34
All fungi 5
Candida albicans 2
Candida non-albicans 2
Cryptococcus neoformans 1
Including all microorganisms isolated in the blood cultures; there were 31
polymicrobial bloodstream infections.
aFour were methicillin-resistant Staphylococcus aureus.
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therapy, in patients with a high (> III) Pneumonia Severity
Score class [15].
The overall mortality of patients with community-acquired
BSI ranges between 39 and 42% [11,16,17], slightly lower
than our mortality rate (45.6%), reinforcing the severity of
our patient population.
However, it is not clear if the presence of BSI increases
disease severity itself or if it is only a marker of disease
severity. In a cohort of 2076 infected surgical patients [18],
the presence of BSI (17.5%) was not independently associ-
ated with mortality. The authors matched the patients with
or without BSI according to their primary site of infection,
APACHE II score, age and class of infecting organism [18].
According to that model, the presence of a hospital-acquired
BSI was not associated with increased mortality, neither in
pneumonia nor in abdominal infections. In contrast, in our
study addressing only patients with CAS, the presence of BSI
was independently associated with ICU and hospital mortal-
ity, even after adjusting for disease severity. Similar ﬁndings
were noted in a recent study of patients with necrotizing fas-
ciitis [19], especially when associated with group A strepto-
coccus. Another study noted an independent association
between BSI and the risk of developing septic shock in a
cohort of patients admitted to a medical ward with new
onset fever (OR 2.09, p 0.18) [20].
Initial early and adequate antibiotic therapy is considered
of the utmost importance for the treatment of critically ill
patients with sepsis [21]. In fact Ibrahim et al. [22] found a
close relationship between initial antibiotic inadequacy and
mortality in patients with BSI admitted to an ICU (AOR 6.9,
p <0.001). In our study, 18.4% of patients with CAS at hospi-
tal admission (14.6% of patients with a BSI) received initial
inadequate antibiotic therapy, although this did not signiﬁ-
cantly impact mortality. An initial antibiotic policy adjusted to
the patients’ risk factors (including the presence of HCAI)
and to the severity of the disease, may have contributed to
this high rate of antibiotic adequacy.
The most common isolated pathogens in patients with
CAS and BSI in our study (Table 3) and in others [11,17]
were, as would be expected, methicillin-sensitive Staphylococ-
cus aureus, Escherichia coli and Streptococcus pneumoniae. Nev-
ertheless, the observed hospital mortality was still over 40%,
increasing with sepsis severity. In another prospective multi-
center study, addressing ICU patients, with community-
acquired and hospital-acquired BSI, the overall mortality rate
was 38.7%. Age, illness severity and the presence of immuno-
suppression, but not inadequate initial antibiotic therapy (OR
0.89; 95% CI 0.61–1.3; p 0.55), were the identiﬁed mortality
risk factors [16].
In Table 4 we present the seasonal variation of the agents
responsible for BSI. Streptococcus pneumoniae was found to
be more common during the winter, which was probably
related to the lower temperature and also to the increased
circulation of respiratory winter virus, especially respiratory
syncytial virus and inﬂuenza virus [23]. On the other hand,
Escherichia coli BSI were shown to be more prevalent in hot
weather, during summer [24,25], as in our study.
In our study the presence of a BSI in CAS patients at hos-
pital admission was associated with high mortality. Patients
with BSI may have a larger burden of microorganisms,
responsible for greater clinical severity and a high early mor-
tality risk. However, in our study, this difference in mortality
of patients with and without BSI only became statistically dif-
ferent after day 9 of ICU stay (Fig. 1).
Nevertheless, at day 4 the patients with BSI were more
often dependent on vasopressors, probably reﬂecting a high
clinical severity or a slower resolution of infection (Table 2).
This dependence on vasopressors has been classiﬁed else-
where as response failure and shown to be associated with
increased mortality [26].
Both temperature and C-reactive protein were signiﬁ-
cantly higher at ICU admission in patients with BSI, but with
substantial overlap of values, precluding their use for diagno-
sis. However, daily monitoring of C-reactive protein concen-
tration may prove to be useful. A recent study from our
group clearly showed that the C-reactive protein trend helps
to identify CAS patients who are not responding to anti-
biotic therapy, who had an increase risk of dying, as early as
the ﬁrst days of antibiotic therapy [7].
Our study has several important strengths. It is one of the
largest multi-centre epidemiological studies evaluating BSI in
critically ill patients with CAS. It prospectively evaluated
patients admitted with CAS for a 12-month period, allowing
the evaluation of effects related to seasonal variation. All
TABLE 4. Seasonal distribution of isolated microorganisms in bloodstream infections
Total (n = 160) Spring (n = 42) Summer (n = 46) Autumn (n = 34) Winter (n = 38) p-value*
Microorganism
Gram-negative 60 (38) 15 (36) 24 (52) 14 (41) 7 (18) 0.024
Gram-positive 71 (44) 17 (40) 17 (37) 12 (35) 25 (66)
Mixeda 29 (18) 10 (24) 5 (11) 8 (24) 6 (16)
*Chi-square test; aIncludes polymicrobial mixed infections.
Siginiﬁcant p-values are indicted in bold.
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patients were followed until death or hospital discharge,
which unveiled differences in cumulative mortality through
time. Data quality has been evaluated through an external
audit randomly reviewing selected patient protocols. How-
ever, we recognize that our study has some limitations. Its
non-randomized, observational design may have induced
some unknown bias in the treatment of patients with CAS,
especially as ICU admission criteria were deﬁned by local
policy and not by protocol. Furthermore, we have no data
concerning antibiotic therapy before hospital admission or
CAS patients not admitted to ICU.
Conclusion
In CAS patients receiving early appropriate antibiotic ther-
apy, BSI at hospital admission was independently associated
with late resolution of sepsis and increased ICU and hospital
late mortality, noted after 9 days of ICU stay. There was a
seasonal variation in the agents responsible for BSI.
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